K-BioCELF
K-BioCELF Inc., was established in March 2019, as a Bio Venture company whose main businesses are the development of technology-based Automated Bioprocess Robotic Systems, in vitro diagnostics, and new drugs, based on core technology.
K-BioCELF pioneers advanced bioprocess automation through products such as the CELF™ System for advanced biopharmaceutical automatic manufacturing devices and the CELB ACE™ System for in vitro diagnostic medical devices.
Major products include CELF™ (Automated Cell Culture System), CELB ACE™ System (Liquid Biopsy System, IVD), CELB™ SEP-STD (Automated Blood Separation System), CELP™ (Artificial Skin Model Production System), CELH™ DDR-SP (Reagent Dispensing System), CELH™ DST (Automated Microbial Inoculation System), and in vitro diagnostic kits. These products cover a wide spectrum of biotechnology and medical applications.
By partnering with government agencies, we’re developing prototypes for bioprocess automation equipment, and contributing to national healthcare initiatives.
We’re scaling up production to meet the demand for biopharmaceuticals, improving accessibility and quality of life for patients worldwide.
Through our initiatives, we aim to lead the healthcare revolution and leverage automation to improve the efficiency and effectiveness of diagnosis and treatment.
- For more information, visit: www.k-biocelf.com
